Pioglitazone rapidly reduces neuropathic pain through astrocyte and nongenomic PPARγ mechanisms

Pain

Volumn 156, Issue 3, 2015, Pages 469-482

  Griggs, Ryan B ^a   Donahue, Renee R ^a   Morgenweck, Jenny ^a,b   Grace, Peter M ^c   Sutton, Amanda ^a   Watkins, Linda R ^c   Taylor, Bradley K ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Astrocyte; Neuropathic; Nongenomic; Pain; Pioglitazone; PPAR gamma

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ANISOMYCIN; GLIAL FIBRILLARY ACIDIC PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROTEIN FOS; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CAPSAICIN; PROTEIN V FOS;

ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CEREBROSPINAL FLUID FLOW; COLD SENSITIVITY; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MALE; MECHANICAL HYPERALGESIA; MOTOR COORDINATION; NERVE INJURY; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SPINAL CORD; SPINAL CORD DORSAL HORN; SPINAL CORD VENTRAL HORN; WESTERN BLOTTING; ANALYSIS OF VARIANCE; ANIMAL; ANIMAL DISEASE; AREA UNDER THE CURVE; COMPLICATION; DRUG EFFECTS; HYPERALGESIA; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; NEURALGIA; PAIN THRESHOLD; PATHOLOGY; PHYSIOLOGY; PSYCHOMOTOR PERFORMANCE; SPRAGUE DAWLEY RAT;

ANALYSIS OF VARIANCE; ANIMAL DISEASES; ANIMALS; AREA UNDER CURVE; ASTROCYTES; CAPSAICIN; GLIAL FIBRILLARY ACIDIC PROTEIN; HYPERALGESIA; HYPOGLYCEMIC AGENTS; INJECTIONS, INTRAVENTRICULAR; MALE; NEURALGIA; NOCICEPTION; ONCOGENE PROTEINS V-FOS; PAIN THRESHOLD; PPAR GAMMA; PSYCHOMOTOR PERFORMANCE; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD DORSAL HORN; THIAZOLIDINEDIONES;

EID: 84964613681     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1097/01.j.pain.0000460333.79127.be     Document Type: Article

References (97)

1. Andersson DA, Gentry C, Light E, Vastani N, Vallortigara J, Bierhaus A, Fleming T, Bevan S. Methylglyoxal Evokes Pain by Stimulating TRPA1. PLoS One 2013;8:e77986.
2. Asiedu MN, Tillu DV, Melemedjian OK, Shy A, Sanoja R, Bodell B, Ghosh S, Porreca F, Price TJ. Spinal protein kinase M zeta underlies the maintenance mechanism of persistent nociceptive sensitization. J Neurosci 2011;31:6646-53.
3. Beaudry H, Dubois D, Gendron L. Activation of spinal mu-and deltaopioid receptors potently inhibits substance P release induced by peripheral noxious stimuli. J Neurosci 2011;31:13068-77.
4. Beggs S, Salter MW. Stereological and somatotopic analysis of the spinal microglial response to peripheral nerve injury. Brain Behav Immun 2007; 21:624-33.
5. Bell PB, Rundquist I, Svensson I, Collins VP. Formaldehyde sensitivity of a GFAP epitope, removed by extraction of the cytoskeleton with high salt. J Histochem Cytochem 1987;35:1375-80.
6. Bernardo A, Minghetti L. Regulation of Glial Cell Functions by PPARgamma Natural and Synthetic Agonists. PPAR Res 2008;2008:864140.
7. Bonin RP, De Koninck Y. A spinal analog of memory reconsolidation enables reversal of hyperalgesia. Nat Neurosci 2014;17:1043-5.
8. Brederson JD, Kym PR, Szallasi A. Targeting TRP channels for pain relief. Eur J Pharmacol 2013;716:61-76.
9. Chacur M, Gutiérrez JM, Milligan ED,Wieseler-Frank J, Britto LRG, Maier SF, Watkins LR, Cury Y. Snake venom components enhance pain upon subcutaneous injection: an initial examination of spinal cord mediators. PAIN 2004;111:65-76.
10. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994; 53:55-63.
11. Chen FL, Dong YL, Zhang ZJ, Cao DL, Xu J, Hui J, Zhu L, Gao YJ. Activation of astrocytes in the anterior cingulate cortex contributes to the affective component of pain in an inflammatory pain model. Brain Res Bull 2012;87:60-6.
12. Chen Q, Chen J, Sun T, Shen J, Shen X, Jiang H. A yeast two-hybrid technology-based system for the discovery of PPARg agonist and antagonist. Anal Biochem 2004;335:253-9.
13. Churi SB, Abdel-Aleem OS, Tumber KK, Scuderi-Porter H, Taylor BK. Intrathecal rosiglitazone acts at peroxisome proliferator-activated receptorgamma to rapidly inhibit neuropathic pain in rats. J Pain 2008;9:639-49.
14. Coggeshall RE. Fos, nociception and the dorsal horn. Prog Neurobiol 2005;77:299-352.
15. Corder G, Siegel A, Intondi AB, Zhang X, Zadina JE, Taylor BK. A novel method to quantify histochemical changes throughout the mediolateral axis of the substantia gelatinosa after spared nerve injury: characterization with TRPV1 and substance P. J Pain 2010;11:388-98.
16. Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and antihyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. PAIN 2008;139:541-50.
17. Cristiano L, Bernardo A, Ceru MP. Peroxisome proliferator-activated receptors (PPARs) and peroxisomes in rat cortical and cerebellar astrocytes. J Neurocytol 2001;30:671-83.
18. Decosterd I, Woolf CJ. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. PAIN 2000;87:149-58.
19. Dello Russo C, Gavrilyuk V, Weinberg G, Almeida A, Bolanos JP, Palmer J, Pelligrino D, Galea E, Feinstein DL. Peroxisome proliferator-activated receptor g thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem 2003;278:5828-36.
20. Dixon WJ. Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 1980;20:441-62.
21. Eng LF, Ghirnikar RS, Lee YL. Glial fibrillary acidic protein: GFAP-thirtyone years (1969-2000). Neurochem Res 2000;25:1439-51.
22. Fehrenbacher JC, LoVerme J, Clarke W, Hargreaves KM, Piomelli D, Taylor BK. Rapid pain modulation with nuclear receptor ligands. Brain Res Rev 2009;60:114-24.
23. Feinstein DL. Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease. Diabetes Technol Ther 2003; 5:67-73.
24. Filardo EJ, Quinn JA, Frackelton AR, Bland KI. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 2002;16: 70-84.
25. Frey U, Krug M, Reymann KG, Matthies H. Anisomycin, an inhibitor of protein synthesis, blocks late phases of LTP phenomena in the hippocampal CA1 region in vitro. Brain Res 1988;452:57-65.
26. Gao YJ, Ji RR. c-Fos and pERK, which is a better marker for neuronal activation and central sensitization after noxious stimulation and tissue injury? Open Pain J 2009;2:11-7.
27. Grace PM, Hutchinson MR, Maier SF, Watkins LR. Pathological pain and the neuroimmune interface. Nat Rev Immunol 2014;14:217-31.
28. Gras D, Chanez P, Urbach V, Vachier I, Godard P, Bonnans C. Thiazolidinediones induce proliferation of human bronchial epithelial cells through the GPR40 receptor. Am J Physiol Lung Cell Mol Physiol 2009;296:L970-8.
29. Grollman AP, Walsh Wttao M. Inhibitors of protein biosynthesis: II. Mode of action of anisomycin. J Biol Chem 1967;242:3226-3.
30. Gruber-Schoffnegger D, Drdla-Schutting R, Honigsperger C, Wunderbaldinger G, Gassner M, Sandkuhler J. Induction of thermal hyperalgesia and synaptic long-term potentiation in the spinal cord lamina I by TNF-alpha and IL-1beta is mediated by glial cells. J Neurosci 2013;33:6540-51.
31. Gurley C, Nichols J, Liu S, Phulwani NK, Esen N, Kielian T. Microglia and astrocyte activation by toll-like receptor ligands: modulation by PPARgamma agonists. PPAR Res 2008;2008:453120.
32. Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. PAIN 1988;32:77-88.
33. Harris JA. Using c-fos as a neuralmarker of pain. Brain Res Bull 1998;45:1-8.
34. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, O'Banion K, Klockgether T, Van Leuven F, Landreth GE. Acute treatment with the PPAR{gamma} agonist pioglitazone and ibuprofen reduces glial inflammation and A{beta}1-42 levels in APPV717I transgenic mice. Brain 2005;128:1442-53.
35. Hossaini M, Duraku LS, Saraç C, Jongen JLM, Holstege JC. Differential distribution of activated spinal neurons containing glycine and/or GABA and expressing c-fos in acute and chronic pain models. PAIN 2010;151: 356-65.
36. Hunter RL, Bing G. Agonism of peroxisome proliferator receptor-gamma may have therapeutic potential for neuroinflammation and Parkinson's disease. Curr Neuropharmacol 2007;5:35-46.
37. Hunter RL, Choi DY, Ross SA, Bing G. Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats. Neurosci Lett 2008;432:198-201.
38. Ikeda H, Mochizuki K, Murase K. Astrocytes are involved in long-term facilitation of neuronal excitation in the anterior cingulate cortex of mice with inflammatory pain. PAIN 2013;154:2836-43.
39. Jia HB, Wang XM, Qiu LL, Liu XY, Shen JC, Ji Q, Yang JJ. Spinal neuroimmune activation inhibited by repeated administration of pioglitazone in rats after L5 spinal nerve transection. Neurosci Lett 2013;543:130-35.
40. Jia H, Zhu S, Ji Q, Hui K, Duan M, Xu J, Li W. Repeated administration of pioglitazone attenuates development of hyperalgesia in a rat model of neuropathic pain. Exp Clin Psychopharmacol 2010;18:359-65.
41. Joels M, Sarabdjitsingh RA, Karst H. Unraveling the time domains of corticosteroid hormone influences on brain activity: rapid, slow, and chronic modes. Pharmacol Rev 2012;64:901-38.
42. Kapadia R, Yi JH, Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci 2008;13: 1813-26.
43. Kim SJ, Thomas KS, Calejesan AA, Zhuo M. Macromolecular synthesis contributes to nociceptive response to subcutaneous formalin injection in mice. Neuropharmacology 1998;37:1091-3.
44. Krug M, Lössner B, Ott T. Anisomycin blocks the late phase of long-term potentiation in the dentate gyrus of freely moving rats. Brain Res Bull 1984;13:39-42.
45. Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, Consler TG, Davis RG, Hull-Ryde EA, Lenhard JM, Patel L, Plunket KD, Shenk JL, Stimmel JB, Therapontos C, Willson TM, Blanchard SG. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 2002;41:6640-50.
46. Levin ER. Rapid signaling by steroid receptors. Am J Physiol Regul Integr Comp Physiol 2008;295:R1425-1430.
47. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005;67:15-19.
48. LoVerme J, Russo R, La Rana G, Fu J, Farthing J, Mattace-Raso G, Meli R, Hohmann A, Calignano A, Piomelli D. Rapid broad-spectrumanalgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther 2006;319:1051-61.
49. Lu YC, Chen CW, Wang SY, Wu FS. 17{beta}-estradiol mediates the sex difference in capsaicin-induced nociception in rats. J Pharmacol Exp Ther 2009;331:1104-110.
50. Luconi M, Cantini G, Serio M. Peroxisome proliferator-activated receptor gamma (PPARgamma): is the genomic activity the only answer? Steroids 2010;75:585-94.
51. Ma D, Lu L, Boneva NB, Warashina S, Kaplamadzhiev DB, Mori Y, Nakaya MA, Kikuchi M, Tonchev AB, Okano H, Yamashima T. Expression of free fatty acid receptor GPR40 in the neurogenic niche of adult monkey hippocampus. Hippocampus 2008;18:326-33.
52. Ma D, Tao B, Warashina S, Kotani S, Lu L, Kaplamadzhiev DB, Mori Y, Tonchev AB, Yamashima T. Expression of free fatty acid receptor GPR40 in the central nervous system of adult monkeys. Neurosci Res 2007;58: 394-401.
53. Maeda T, Kiguchi N, Kobayashi Y, Ozaki M, Kishioka S. Pioglitazone attenuates tactile allodynia and thermal hyperalgesia in mice subjected to peripheral nerve injury. J Pharmacol Sci 2008;108:341-7.
54. Maeda T, Kishioka S. PPAR and Pain. Int Rev Neurobiol 2009;85:165-77.
55. Maeshiba Y, Kiyota Y, Yamashita K, Yoshimura Y, Motohashi M, Tanayama S. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung 1997;47:29-35.
56. Maggiolini M, Picard D. The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J Endocrinol 2010;204:105-14.
57. Mestre C, Pelissier T, Fialip J, Wilcox G, Eschalier A. A method to perform direct transcutaneous intrathecal injection in rats. J Pharmacol Toxicol Methods 1994;32:197-200.
58. Moreno S, Farioli-Vecchioli S, Cerù MP. Immunolocalization of peroxisome proliferator-activated receptors and retinoid x receptors in the adult rat CNS. Neuroscience 2004;123:131-45.
59. Morgenweck J, Abdel-aleem OS, McNamara KC, Donahue RR, Badr MZ, Taylor BK. Activation of peroxisome proliferator-activated receptor [gamma] in brain inhibits inflammatory pain, dorsal horn expression of Fos, and local edema. Neuropharmacology 2010;58:337-45.
60. Morgenweck J, Griggs RB, Donahue RR, Zadina JE, Taylor BK. PPARg activation blocks development and reduces established neuropathic pain in rats. Neuropharmacology 2013;70:236-46.
61. Nakamoto K, Nishinaka T, Matsumoto K, Kasuya F, Mankura M, Koyama Y, Tokuyama S. Involvement of the long-chain fatty acid receptor GPR40 as a novel pain regulatory system. Brain Res 2012;1432:74-83.
62. Nakamoto K, Nishinaka T, Sato N, Mankura M, Koyama Y, Kasuya F, Tokuyama S. Hypothalamic GPR40 signaling activated by free long chain fatty acids suppresses CFA-induced inflammatory chronic pain. PLoS One 2013;8:e81563.
63. Ohtori S, Takahashi K, Moriya H, Myers RR. TNF-alpha and TNF-alpha receptor type 1 upregulation in glia and neurons after peripheral nerve injury: studies inmurineDRGand spinal cord. Spine (PhilaPa 1976) 2004;29:1082-8.
64. Oliveira ACP, Bertollo CM, Rocha LTS, Nascimento JEB, Costa KA, Coelho MM. Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma. Eur J Pharmacol 2007;561:194-201.
65. Orii R, Ohashi Y, Guo T, Nelson LE, Hashimoto T, Maze M, Fujinaga M. Evidence for the involvement of spinal cord alpha1 adrenoceptors in nitrous oxide-induced antinociceptive effects in Fischer rats. Anesthesiology 2002;97:1458-65.
66. Pancani T, Anderson KL, Porter NM, Thibault O. Imaging of a glucose analog, calcium and NADH in neurons and astrocytes: dynamic responses to depolarization and sensitivity to pioglitazone. Cell Calcium 2011;50:548-8.
67. Park SW, Yi JH, Miranpuri G, Satriotomo I, Bowen K, Resnick DK, Vemuganti R. Thiazolidinedione class of peroxisome proliferatoractivated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther 2007;320:1002-2.
68. Parsons RG, Gafford GM, Baruch DE, Riedner BA, Helmstetter FJ. Longterm stability of fear memory depends on the synthesis of protein but not mRNA in the amygdala. Eur J Neurosci 2006;23:1853-9.
69. Parsons RG, Riedner BA, Gafford GM, Helmstetter FJ. The formation of auditory fear memory requires the synthesis of protein and mRNA in the auditory thalamus. Neuroscience 2006;141:1163-70.
70. Paxinos G, Watson C. The rat brain in stereotaxic coordinates: Elsevier Academic Press, Inc., 1997.
71. Rogue A, Spire C, Brun M, Claude N, Guillouzo A. Gene expression changes induced by PPAR gamma agonists in animal and human liver. PPAR Res 2010;2010:325183.
72. Rosenblum K, Meiri N, Dudai Y. Taste memory: The role of protein synthesis in gustatory cortex. Behav Neural Biol 1993;59:49-56.
73. Rowan MP, Berg KA, Milam SB, Jeske NA, Roberts JL, Hargreaves KM, Clarke WP. 17b-estradiol rapidly enhances bradykinin signaling in primary sensory neurons in vitro and in vivo. J Pharmacol Exp Ther 2010;335:190-6.
74. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45:1661-9.
75. Sauerbeck A, Gao J, Readnower R, Liu M, Pauly JR, Bing G, Sullivan PG. Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury. Exp Neurol 2011;227:128-35.
76. Schafe GE, LeDoux JE. Memory consolidation of auditory pavlovian fear conditioning requires protein synthesis and protein kinase A in the amygdala. J Neurosci 2000;20:RC96.
77. Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci 2007;10:1361-8.
78. Seabrook GR, Sutton KG, Jarolimek W, Hollingworth GJ, Teague S, Webb J, Clark N, Boyce S, Kerby J, Ali Z, Chou M, Middleton R, Kaczorowski G, Jones AB. Functional properties of the high-affinity TRPV1 (VR1) vanilloid receptor antagonist (4-Hydroxy-5-iodo-3-methoxyphenylacetate ester) iodo-resiniferatoxin. J Pharmacol Exp Ther 2002;303:1052-60.
79. Simone DA, Baumann TK, LaMotte RH. Dose-dependent pain and mechanical hyperalgesia in humans after intradermal injection of capsaicin. PAIN 1989;38:99-107.
80. Simone DA, Ngeow JY, Putterman GJ, LaMotte RH. Hyperalgesia to heat after intradermal injection of capsaicin. Brain Res 1987;418:201-3.
81. Small KM, Nag S, Mokha SS. Activation ofmembrane estrogen receptors attenuates opioid receptor-like1 receptor-mediated antinociception via an ERK-dependent non-genomic mechanism. Neuroscience 2013;255: 177-90.
82. Storer PD, Xu J, Chavis JA, Drew PD. Cyclopentenone prostaglandins PGA2 and 15-deoxy-delta12,14 PGJ2 suppress activation of murine microglia and astrocytes: implications for multiple sclerosis. J Neurosci Res 2005;80:66-74.
83. Takahashi Y, Hasegawa-Moriyama M, Sakurai T, Inada E. The macrophage-mediated effects of the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone attenuate tactile allodynia in the early phase of neuropathic pain development. Anesth Analg 2011;113: 398-404.
84. Taylor BK. Pathophysiologic mechanisms of neuropathic pain. Curr Pain Headache Rep 2001;5:151-61.
85. Taylor BK, Abhyankar SS, Vo NT, Kriedt CL, Churi SB, Urban JH. Neuropeptide Y acts at Y1 receptors in the rostral ventral medulla to inhibit neuropathic pain. PAIN 2007;131:83-95.
86. Taylor BK, Holloway D, Printz MP. A unique central cholinergic deficit in the spontaneously hypertensive rat: physostigmine reveals a bradycardia associated with sensory stimulation. J Pharmacol Exp Ther 1994;268: 1081-90.
87. Todd AJ, Spike RC, Brodbelt AR, Price RF, Shehab SAS. Some inhibitory neurons in the spinal cord develop c-fos-immunoreactivity after noxious stimulation. Neuroscience 1994;63:805-16.
88. Vega-Avelaira D, Moss A, Fitzgerald M. Age-related changes in the spinal cord microglial and astrocytic response profile to nerve injury. Brain Behav Immun 2007;21:617-23.
89. Wang H, GuoW, Yang K,Wei F, Dubner R, Ren K. Contribution of primary afferent input to trigeminal astroglial hyperactivity, cytokine induction and NMDA receptor phosphorylation. Open Pain J 2010;2010:144-52.
90. Watkins LR, Milligan ED, Maier SF. Glial activation: A driving force for pathological pain. Trends Neurosciences 2001;24:450-5.
91. Wei F, Guo W, Zou S, Ren K, Dubner R. Supraspinal glial-neuronal interactions contribute to descending pain facilitation. J Neurosci 2008; 28:10482-95.
92. Yamashita A, Hamada A, Suhara Y, Kawabe R, Yanase M, Kuzumaki N, Narita M, Matsui R, Okano H, Narita M. Astrocytic activation in the anterior cingulate cortex is critical for sleep disorder under neuropathic pain. Synapse 2014;68:235-47.
93. Yonutas HM, Sullivan PG. Targeting PPAR isoforms following CNS injury. Curr Drug Targets 2013;14:733-42.
94. Zhang J, De Koninck Y. Spatial and temporal relationship between monocyte chemoattractant protein-1 expression and spinal glial activation following peripheral nerve injury. J Neurochem 2006;97:772-83.
95. Zhang Y, Lu N, Zhao ZQ, Zhang YQ. Involvement of estrogen in rapid pain modulation in the rat spinal cord. Neurochem Res 2012;37:2697-705.
96. Zhuang ZY, Kawasaki Y, Tan PH, Wen YR, Huang J, Ji RR. Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkine. Brain Behav Immun 2007;21:642-51.
97. Zhuang ZY, Wen YR, Zhang DR, Borsello T, Bonny C, Strichartz GR, Decosterd I, Ji RR. A peptide c-Jun N-terminal kinase (JNK) inhibitor blocks mechanical allodynia after spinal nerve ligation: respective roles of JNK activation in primary sensory neurons and spinal astrocytes for neuropathic pain development and maintenance. J Neurosci 2006;26: 3551-60.